Healthy Brain and Child Development National Consortium Data Coordinating Center

项目摘要/摘要 怀孕期间阿片类药物的使用很普遍，并与怀孕个体的不良后果有关 和发育中的孩子。产前阿片类药物暴露与广泛的阴性胎儿和儿童相关 结果，包括胎儿发育减慢、早产、出生体重降低、先天性缺陷等增加 新生儿保健，以及以后行为(如焦虑、注意力不集中)、认知(如记忆)的高风险 缺陷、语言习得延迟)和新陈代谢问题。尽管阿片类药物的使用与不良反应有关 孕产妇、胎儿和儿童的结局、产生这些后果的机制和潜在的后果 产前阿片类药物暴露对儿童健康和发育(如大脑和行为)的影响在很大程度上仍然存在 未被开发的。这种病因学知识的缺乏导致了治疗、预防和缓解的停滞。 努力使个人和家庭容易受到不良后果的影响。 健康大脑和儿童发展(HBCD)研究是一项25个地点的纵向前瞻性研究 美国早期儿童发展将评估广泛的生物学(例如，神经成像、遗传学、 表观遗传学)、行为(例如认知和情绪调节)、经验(例如创伤)、社会(例如， 在约7,500名具有全国代表性的孕妇中调查了健康(例如，精神病理学)因素 以及他们的孩子从怀孕到童年中期。HBCD研究的一个主要目标是增加对 产前接触物质的潜在后果。它将被丰富用于母体物质使用 在怀孕期间(即，约25%的样本在怀孕期间使用阿片类药物、大麻、酒精和/或烟草 怀孕和总样本的12%将使用阿片类药物)，并提供了一个独特的机会来告知我们的 了解与怀孕期间使用阿片类药物相关的不良后果是如何产生的。虽然 HBCD将是美国最大的关于早期大脑和儿童发展结果的长期研究，核心是 议定书不包括收集投放的生物检疫剂。作为回应，本行政副刊 致NIDA/ORWH特别利益的行政补充通知：Hear倡议：Biospecimen收藏 在怀孕期间(非-DA-23-005)建议利用现有基础设施并扩大提供的服务 通过HBCD数据协调中心(HDCC)全面支持HBCD生物样品收藏的扩展 包括分娩标本(胎盘、脐带组织、脐带血)。送货样本将从一个 HBCD研究参与者的代表性样本，涉及多达14个地点(以及超过2,000名参与者 HBCD网站响应这一NOSI提交申请)。这将提供前所未有的资源 为更大的科学界创造机会，全面评估病理生理学 阿片类药物和多物质在妊娠和不良反应中的作用机制 这将有助于改善新生儿、婴儿和/或产妇的健康状况，进而促进创新的预防战略。

PROJECT SUMMARY/ABSTRACT Opioid use during pregnancy is widespread and associated with adverse outcomes for the pregnant individual and the developing child. Prenatal opioid exposure is associated with a wide range of negative fetal and child outcomes, including reduced fetal growth, premature birth, lower birthweight, congenital defects, increased neonatal healthcare, and heightened risk for later behavioral (e.g., anxiety, inattention), cognitive (e.g., memory deficits, delayed language acquisition), and metabolic problems. Despite opioid use being linked to adverse maternal, fetal, and child outcomes, the mechanisms through which these arise and the potential consequences of prenatal opioid exposure for child health and development (e.g., brain and behavior) remain largely unexplored. This lack of etiologic knowledge has contributed to stagnant treatment, prevention, and mitigation efforts leaving individuals and families susceptible to reverberating adverse outcomes. The HEALthy Brain and Child Development (HBCD) Study is a 25-site longitudinal prospective study of early child development in the US that will assess a broad spectrum of biological (e.g., neuroimaging, genetics, epigenetics), behavioral (e.g., cognition and emotional regulation), experiential (e.g., trauma), social (e.g., racism), and health (e.g., psychopathology) factors among ~7,500 nationally-representative pregnant women and their children from pregnancy to mid-childhood. A major goal of the HBCD study is to increase understanding of the potential consequences of prenatal substance exposures. It will be enriched for maternal substance use during pregnancy (i.e., ~25% of the sample will be using opioids, cannabis, alcohol, and/or tobacco during pregnancy and 12% of the total sample will be using opioids) and offers a unique opportunity to inform our understanding of how the adverse consequences associated with opioid use during pregnancy arise. Although HBCD will be the largest long-term study of early brain and child development outcomes in the US, the core protocol does not include the collection of delivery biospecimens. This Administrative Supplement in response to NIDA/ORWH Administrative Supplement Notice of Special Interests: HEAL Initiative: Biospecimen Collection in Pregnancy (NOT-DA-23-005) proposes to leverage existing infrastructure and expand services provided through the HBCD Data Coordinating Center (HDCC) to fully support expansion of HBCD biospecimen collection to include delivery specimens (placenta, cord tissue, cord blood). Delivery samples will be collected from a representative sample of HBCD study participants across up to 14 sites (and over 2,000 participants across HBCD sites submitting applications in response to this NOSI). This will provide an unprecedented resource generating opportunity for the larger scientific community to comprehensively evaluate pathophysiological mechanisms that mediate the connection between opioid and polysubstance use during pregnancy and adverse neonatal, infant, and/or maternal health outcomes and, in turn, inform innovative preventive strategies.